

S/N 08/927,939



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	David J. Grainger et al.	Examiner:	Joseph Murphy
Serial No.:	08/927,939	Group Art Unit:	1646
Filed:	September 11, 1997	Docket:	1543.001US1
Title:	COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE		

INFORMATION DISCLOSURE STATEMENT

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

INFORMATION DISCLOSURE STATEMENT

Serial No :08/927,939

Filing Date: September 11, 1997

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Page 2

Dkt: 1543.001US1


The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

DAVID J. GRAINGER ET AL.


By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date September 2, 2004 By 
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 2 day of September, 2004.

Name Gina M. Uphus


Signature

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	08/927,939
	Filing Date	September 11, 1997
	First Named Inventor	Grainger, David
	Group Art Unit	1646
	Examiner Name	Murphy, Joseph
Sheet 1 of 2		Attorney Docket No: 1543.001US1

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-5,770,609	06/23/1998	Grainger, David J., et al.	514	319	06/07/1995

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	WO-00/00821	01/06/2000	Ullman, Edwin F.	G01N	33/48	
	WO-92/14455	09/03/1992	Kaplan, , et al.	A61K	31/21	


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS					T ²
Examiner Initials*	Cite No ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		BEERS, MARK , et al., "Myeloproliferative Disorders.....", <u>The Merck Manual 7th Edition</u> , (1999),1474-1476 & 895-902			
		BUSINCO, L. , et al., "From Atopic Dermatitis to Asthma: The Risk Factors and Preventive Measures", <u>Pediatric Pulmonology, Supplement</u> , 16, (1997),19-20			
		ELSON, C. , et al., "Experimental Models of Inflammatory Bowel Disease", <u>Gastroenterology</u> , 109, (1995),pp. 1344-1367			
		FOX, DANIEL J., "Design, Synthesis, and Preliminary Pharmacological Evaluation of N-Acyl-3-aminoglutarimides as Broad-Spectrum Chemokine Inhibitors in Vitro and Anti-inflammatory Agents in Vivo", <u>J. Med. Chem.</u> , 45, (2002),pp. 360-370			
		FRECKER, M. , et al., "Immunological Associations in Familial and Non-Familial Alzheimer Patients and Their Families", <u>The Canadian Journal of Neurological Sciences</u> , 21, (1994),pp. 112-119			
		IVACKO, J. , et al., "Hypoxic-Ischemic Injury Induces Monocyte Chemoattractant Protein-1 Expression in Neonatal Rat Brain", <u>Journal of Cerebral Blood Flow and Metabolism</u> , 17, (1997),pp. 759-770			
		JIN, D. , et al., "Complement 4 Locus II Gene Deletion and DQA1*0301 Gene: Genetic Risk Factors for IgA Nephropathy and Henoch-Schonlein Nephritis", <u>Nephron</u> , 73, (1996),pp. 390-395			
		KARPUS, W. , et al., "An Important Role for the Chemokine Macrophage Inflammatory Protein-1alpha in the Pathogenesis of the T Cell-Mediated Autoimmune Disease., Experimental Autoimmune Encephalomyelitis", <u>The Journal of Immunology</u> , (1995),pp. 5003-5010			
		KUNKEL, S. , et al., "The role of chemokines in inflammatory joint disease", <u>Journal of Leukocyte Biology</u> , 59, (1996),pp. 6-12			
		LUCCHINETTI, C. , et al., "Risk factors for developing multiple sclerosis after childhood optic neuritis", <u>The American Academy of Neurology</u> , 49, (1997),pp. 1413-1418			

EXAMINER

DATE CONSIDERED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Complete if Known	
Application Number	08/927,939
Filing Date	September 11, 1997
First Named Inventor	Grainger, David
Group Art Unit	1646
Examiner Name	Murphy, Joseph

Sheet 2 of 2

Attorney Docket No: 1543.001US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARONE, M. , et al., "Influence of body composition on the bone mass of post menopausal women", <u>Sao Paulo Medical Journal</u> , 115(6), (1997),pp. 1580-1588	
		MARRA, F. , et al., "Increased Expression of Monocyte Chemotactic Protein-1 during Active Hepatic Fibrogenesis", <u>American Journal of Pathology</u> , 152, (1998),423-430	
		MCGEER, P. , et al., "The inflammatory response system of brain: implications for thereapy of Alzheimer and other neurodegenerative diseases", <u>Brain Research Reviews</u> , 21, (1995),pp. 195-218	
		NALDI, L. , et al., "Dietary factors and the risk of psoriasis. Results of an Italian case-control study", <u>British Journal of Dermatology</u> , 134, (1996),pp. 101-106	
		ONO, K. , et al., "Prevention of Myocardial Reperfusion Injury in Rats by an Antibody against Monocyte Chemotactic and Activating Factor/Monocyte Chemoattractant Protein-1", <u>Laboratory Investigation</u> , 79, (1999),pp. 195-203	
		PAUL, W. M., <u>Fundamental Immunology</u> , Fourth Edition, Lippincott-Raven Publ., Philadelphia,(1999),184-185	
		PAUL, WILLIAM E., "Fundamental Immunology", <u>3rd Edition</u> , (1993),pp250, 1311-1312.	
		REWERS, M , et al., "Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY)", <u>Diabetologia</u> , 39, (1996),pp. 807-812	
		SPENCE, J. , "Advances in atherosclerosis", <u>Bailliere's Clinical Neurology</u> , 4(2), (1995),pp. 191-205	
		SUDA, T. , et al., "Modulation of Osteoclast Differentiation by Local Factors", <u>Bone</u> , 17(2), (1995),pp. 87S-91S	
		VERMA, M. , et al., "Chemokines in acute anterior uveitis", <u>Current Eye Research</u> , (1997),pp. 1202-1208	
		WATANABE, T. , et al., "Atherosclerosis and inflammation Mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA pathway in atherogenesis", <u>International Journal of Cardiology</u> , 66, (1998),pp. S45-S53	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached